Infection with human parvovirus B19 causes fifth disease, acute and chronic red cell aplasia, fetal hydrops, arthropathy, and other disorders. Antiviral antibodies limit B19 infection in vivo; however, the identification of serologic markers of protection has been hampered by the lack of a quantitative assay for parvovirus neutralization. A novel in vitro test for parvovirus neutralization has been developed using reverse transcriptase-polymerase chain reaction to detect viral transcripts in a B19-permissive cell line. Parvovirus neutralizing activity was measured in sera from naturally infected individuals, and common features of sera with high neutralizing capacity were identified as protection correlates. Sera that suppressed B19 replication in vitro demonstrated IgG reactivity with capsid proteins VP1 and VP2, but no linear relationship between antibody titer and neutralizing capacity was observed. Sera from experimental animals and human volunteers immunized with a virus-like particle vaccine candidate exhibited B19 neutralizing titers equal to or greater than those observed in natural infections.
Infection with human parvovirus B19 causes fifth disease, acute and chronic red cell aplasia, fetal hydrops, arthropathy, and other disorders. Antiviral antibodies limit B19 infection in vivo; however, the identification of serologic markers of protection has been hampered by the lack of a quantitative assay for parvovirus neutralization. A novel in vitro test for parvovirus neutralization has been developed using reverse transcriptase-polymerase chain reaction to detect viral transcripts in a B19-permissive cell line. Parvovirus neutralizing activity was measured in sera from naturally infected individuals, and common features of sera with high neutralizing capacity were identified as protection correlates. Sera that suppressed B19 replication in vitro demonstrated IgG reactivity with capsid proteins VP1 and VP2, but no linear relationship between antibody titer and neutralizing capacity was observed. Sera from experimental animals and human volunteers immunized with a virus-like particle vaccine candidate exhibited B19 neutralizing titers equal to or greater than those observed in natural infections.
Human parvovirus B19, first discovered in asymptomatic plasma donors [1] , has been identified as the causative agent of a variety of clinical disorders. In normal children, B19 infection leads to an exanthematous rash called fifth disease [2] . In adults, particularly women, B19 infection may result in persistent arthropathy in ∼50% of patients [3] . Because parvovirus B19 replicates in erythroid progenitor cells, infection can lead to serious complications, including transient aplastic crisis in persons with underlying hemolysis or chronic red cell aplasia in immunodeficient patients [4, 5] . Fetal infection can result in hydrops fetalis, spontaneous abortion early in pregnancy, and congenital anemia [6] .
Multiple studies have highlighted the role of antiviral antibodies in B19 viral clearance [7] [8] [9] [10] [11] . Pooled human immunoglobulin containing B19-specific IgG is effective therapy for persistent B19 infection [10] , suggesting that humoral immunity is predominant in limiting parvovirus infection. However, the lack of quantitative surrogate assays for virus neutralization has hampered the study of neutralizing sera and the identification of markers of protection. The only assay commonly used measures the ability of sera to protect colony-forming erythroid cells (CFU-E) from parvovirus killing in vitro [12] . Several problems with the hematopoietic progenitor cell assay limit its usefulness. Target CFU-E cells for viral infection are obtained from primary bone marrow cultures, which are inconvenient to obtain and contain cells of various differentiation states and lineages, introducing assay-to-assay variability. In addition, neutralization is typically seen at high concentrations of sera, which have highly variable composition and contain cytokines that can affect the growth of erythroid colonies for these reasons. Direct, quantitative comparisons of virus neutralization are difficult to perform by CFU-E analysis. In addition, the week-long incubation period for each CFU-E test makes screening of large numbers of sera cumbersome.
The purpose of this study was to develop a more sensitive, quantitative assay for parvovirus neutralizing capacities of immune sera obtained from individuals infected with B19. We also sought to determine the potential utility of this assay for measuring neutralizing titers in sera after immunization with a B19 vaccine candidate. We developed a new in vitro parvovirus neutralization test using a novel reverse transcriptasepolymerase chain reaction (RT-PCR)-based system.
Materials and Methods
Recombinant B19 antigens. B19 parvovirus empty capsid particles consisting of ∼25% minor capsid protein VP1/75% major capsid protein VP2 were produced as previously described [13] , using a recombinant baculovirus system. CroVP1 was expressed in Escherichia coli and purified as previously described [14] .
Antisera. Clinical specimens and patient diagnoses were obtained from subjects who were screened for clinical studies at the National Institutes of Health or were provided by Larry Anderson (CDC, Atlanta) and Bernard Cohen (Public Health Laboratory Service, London). Sera were also obtained from healthy volunteers immunized with B19 virus-like particles (VLPs) in studies conducted by MedImmune (unpublished data). Sera were complementinactivated at 54ЊC for 30 min before storage at Ϫ20ЊC.
Animal studies and antisera. High-titer anti-B19 capsid antisera were generated by immunizing BALB/c mice and guinea pigs [15] three times with VLPs formulated with aluminum hydroxide (alum) or experimental adjuvants described below. Rhesus monkeys were maintained at the National Heart, Lung and Blood Institute (NIH) nonhuman primate research facility.
Adjuvants. Surfactant-stabilized emulsion adjuvant MF-59 was provided by Dan Granoff (Chiron, Emeryville, CA). MF-59 is an oil-in-water formulation that contains surfactants (Tween 20 and Span 85) along with a metabolizable oil (squalene) emulsified under high-pressure conditions [16] . Nonionic block copolymer adjuvant CRL-2690 was provided by Mark Newman (Vaxcel, Norcross, GA). CRL-2690 is a micellar adjuvant consisting of 12-kDa polyoxypropylene core components copolymerized with 10% polyoxyethylene [17] .
ELISA. Anticapsid and anti-croVP1 antibody levels in sera were measured by ELISA. Immulon II plates (Dynex, Chantilly, VA) were coated with 100 mL of PBS buffer containing 100 ng/mL recombinant antigen overnight at 4ЊC. Plates were washed four times in PBS containing 0.1% Tween 20 (PBS-T), then incubated 60 min at 37ЊC with blocking buffer (PBS containing 5% nonfat milk and 0.1% Tween 20) . After four washes in PBS-T, serum diluted in blocking buffer (100 mL total volume) was added directly to the wells and incubated 60 min at 37ЊC. The plates were washed in PBS-T, then incubated for 60 min with peroxidase-conjugated secondary antibody (goat anti-mouse IgG, 1:5000; Jackson Immunoresearch, West Grove, PA; goat anti-human IgG1, IgG2, IgG3, IgG4, or all IgG, 1:500; Zymed, South San Francisco) at 37ЊC. The plates were washed with PBS-T and developed with 100 mL/well peroxidase substrate (Kirkegaard & Perry, Gaithersburg, MD) for 15 min. Absorbance was read at 405 nm using an ELISA plate reader (Dynex). End-point titer was designated as the reciprocal of the highest serial dilution yielding an optical density reading equal to the reading of the control serum control wells plus 3ϫ SD. All serum dilutions were performed in duplicate.
RT-PCR-based neutralization. Megakaryocytoblastic UT-7 cells adapted to growth in erythropoietin (Epo) were provided by N. Komatsu [18, 19] . UT-7/Epo cells were maintained in RPMI containing 10% fetal calf serum and 2 U/mL recombinant Epo (R&D Systems, Minneapolis). For each neutralization reaction, UT-7/Epo cells were seeded in 1 well of a 24-well plate 5 3 ϫ 10 (Falcon/VWR, South Plainfield, NJ). Neutralizing serum was added at a dilution of 1:200 to 1:20,000, and viremic serum was simultaneously added at a final dilution of 1:25,000. Infected cultures were incubated at 37ЊC for 36 h. After 36 h, the cells were harvested, and total cellular RNA was collected using an RNAgents kit (Promega, Madison, WI) according to the manufacturer's instructions. Parvovirus infection of cultured UT-7/Epo cells was demonstrated by RT-PCR to detect spliced parvovirus mRNA species [20] . As a control for reverse transcription and amplification, cellular b-actin mRNA was simultaneously detected, using primers designed to overlap splice donor/acceptor sites. The location of primers used in these studies, their nucleotide sequences, and the final expected size of PCR amplimers are listed in figure 1 . Total cellular RNA (1 mg/reaction) was diluted in 10 mL (total volume) of nuclease-free distilled H 2 O, incubated at 65ЊC for 5 min to denature the RNA, and stored on ice. Transcription of cDNA was primed using the B19-6 primer and ACT-4 primers in a reaction mix containing 1 mL of a 2.5 mM solution of each primer, 2 mL of a 25 mM stock of dNTPs, 5 mL of 5ϫ RT buffer, 2 mL of 0.1 M dithiothreitol, 0.5 mL of RNase inhibitor, and 0.5 mL of murine leukemia virus RT (Promega) in a 25-mL reaction volume. Each reaction was incubated for 60 min at 37ЊC, then heat-inactivated at 65ЊC for 5 min. An equal volume (5 mL) from each RT reaction was amplified in a 50-mL reaction mix containing 2 mL of a 25 mM stock of each primer, 2 mL of a 2.5 mM dNTP stock, 10 mL of 5ϫ PCR buffer, 10 mL of 25 mM MgCl 2 , and 0.5 mL of Taq polymerase (Perkin-Elmer, Foster City, CA). Thirty-five cycles of PCR were carried out: 94ЊC for 30 s, 58ЊC for 30 s, and 72ЊC for 2 min. A final extension step at 72ЊC for 10 min was performed before analysis of product amplimers by 2% agarose/ethidium bromide gel electrophoresis. Neutralization was reported as the highest dilution of serum that yielded no virus-specific RT-PCR products. All RT-PCR reactions were performed in duplicate.
Results
In vitro parvovirus neutralization assay. An in vitro, quantitative assay for B19 parvovirus neutralization was developed using RT-PCR to amplify virus-specific RNA from a megakaryocytoblastic leukemic cell line (UT-7/Epo [18, 19] ), adapted to growth in erythropoietin and semipermissive for parvovirus replication. Virus-specific transcripts were detectable as early as 12 h after infection. Total RNA was collected, quantitated, and reverse transcribed, and a standard PCR was used to amplify alternatively spliced viral products (262-and 125-bp, figure  1 ) from UT-7/Epo cells exposed to B19 parvovirus in the presence of a dilution of neutralizing serum for 36 h. The cellular transcript control, 635-bp and b-actin-specific, was also amplified using primers spanning splice junctions. PCR products were analyzed by 2% agarose/ethidium bromide electrophoresis.
Actin-and B19-specific products from representative control neutralization reactions are shown in figure 2. Experimental guinea pig serum raised against irrelevant antigen was used in reaction 1 (lanes A and B), while guinea pig serum with a high anticapsid end-point titer [15] was used in reaction 2 (lanes C and D). Virus-specific products of the predicted sizes were observed in lane B, demonstrating that virus neutralization had not occurred in the presence of negative control serum. The identity of the 262-and 125-bp products was confirmed by gel purification of the amplicons and DNA sequencing (data not shown). Virus-specific PCR products were absent in lane D, indicating that input virus had been neutralized in the presence of B19-specific antiserum. Reverse transcription was successful in both reactions, based on comparable actin products in lanes A and C.
To establish the reliability of the RT-PCR neutralization test, the neutralizing capacity of a panel of high-titer anticapsid sera was examined. Representative results for 6 control sera are shown in figure 3 . Immune sera raised in mice against irrelevant antigen did not neutralize parvovirus, as evidenced by virusspecific products observed in reaction 2. Sera with high anti-B19 titer, from animals vaccinated with B19 VLPs (reactions 1, 3, and 4) and immune volunteers (reactions 5 and 6), neutralized input virus. These results confirmed that sera with anti-B19 reactivity from different sources consistently inhibit viral replication. End-point neutralization titers were established by serial dilution of test serum (figure 4), permitting quantitative comparisons of clinical and experimental antiparvovirus neutralization responses.
Clinical correlates of parvovirus neutralization. To determine the spectrum of endogenous parvovirus neutralizing activity in sera from individuals potentially at risk of B19 disease, sera from subjects with various hematologic and oncologic dis- G11G4  2500  A  6966  1250  1250  250  G11G3ϭG4  2500  A  7025  6250  250  250  G11G3ϭG4  1000  NA  7273  6250  250  250  G11G4  1000  A  6887  6250  250  50  G1  2500  A, B  062  31,250  1250  1250  G11G4  5000  N  6850  6250  250  250  G11G4  500  A  7353  1250  250  50  G1  500  D  CS-1  1250  250  250  G11G4  500  N  7124  6250  250  250  G11G3  200  A  7138  1250  1250  1250  G41G1  200  A  CS-3 orders were tested in this RT-PCR neutralization assay. Sera from 2 healthy donors were used as controls; 1 of these had the highest anticapsid response as determined by ELISA. The ability of dilute sera to neutralize parvovirus in vitro is shown in table 1. Neutralizing capacity is reported as the highest dilution of serum that prevents detection of parvovirus-specific products by RT-PCR. To evaluate whether neutralization titers correlated with other serologic responses, end-point titers against whole recombinant capsid and the minor capsid protein VP1 were measured by ELISA. The IgG subclasses of sera reactive with VP1 were also examined and compared with neutralization to assess whether a particular subclass was associated with functional antiparvovirus responses. Of 25 clinical samples studied, 12 neutralized parvovirus in vitro. All neutralizing sera contained antibodies reactive with both recombinant capsid and VP1, consistent with the proposed role of antiparvovirus antibodies in viral clearance. End-point capsid and VP1 reactivity was highly variable. End-point neutralizing titers of these sera also varied, ranging from 200 to 5000. No linear correlation between neutralizing capacity and ELISA titer against capsid ( ) or against VP1 ( ) r ϭ .44 r ϭ .44 was observed. Sera with relatively high anticapsid (16250) and anti-VP1 (1250) end points showed the highest in vitro neutralization. On the other hand, several clinical sera with moderate to high anticapsid titer demonstrated low or no neutralizing activity (e.g., 7340, 7345). We hypothesize that these sera did not recognize important neutralizing epitopes on the B19 virion. No relationship between the specific IgG subclass elicited against VP1 and neutralizing capacity was observed. We extended our analysis of clinical sera to include 8 pairmatched samples from individual donors presumed from clinical history to be infected with B19 (table 2) . Serum samples were obtained during the first clinical visit for parvovirusattributed symptoms, and second samples were collected later during the convalescent period, 2 weeks to 6 months afterward. The detection of anti-B19 IgM responses in only 2 subjects probably reflects delay in serum acquisition after parvovirus infection. In general, convalescent-phase sera demonstrated higher neutralization titers, suggesting maturation of the functional antiparvovirus immune response through the convalescent period, even in the absence of enhanced anticapsid or anti-VP1 specific responses measured by ELISA (e.g., 6726, 8102). In addition, changes in anti-VP1 isotype were detected over time in some volunteers, suggesting that affinity maturation may have coincided in these individuals with improved virus neutralization. The overall magnitude of neutralizing titers in convalescent sera were comparable in range to those of immune subjects selected randomly (table 1) .
Since the passive administration of immune globulin is used therapeutically to arrest acute parvovirus infection in some patients [10] , we measured the in vitro neutralization characteristics of several commercial lots of immune globulin (table 3) . Commercial immunoglobulin lots were adjusted to a midrange of normal serum IgG levels (1000 mg/dL). All lots of immune globulin examined neutralized B19. End points observed (250-1000) were similar to titers found in random donors.
Recombinant B19 capsid elicits neutralizing antibodies. Recombinant capsid proteins have been used to elicit an anti-B19 humoral response as the basis of a candidate vaccine for humans [21] . We examined immune sera generated in mice using the RT-PCR-based neutralization assay (table 4) and found that sera from mice vaccinated with B19 capsid in alum adjuvant neutralized parvovirus in vitro, similar to reported results using the CFU-E neutralization assay [21, 22] . Next, we examined sera from 3 human volunteers immunized three times with B19 VLP formulated in alum (Alhydrogel; Reheis, Berkeley Heights, NJ) (table 4). Of the 3 post-second boost sera from human volunteers, only 1 exhibited moderate humoral reactivity with capsid and VP1 by ELISA and also exhibited a modest in vitro neutralization titer.
Since alterations in formulation, particularly the use of adjuvants, can have dramatic effects on serum antibody titers and functional immune responses, we sought to determine if alternative adjuvants could improve anti-B19 responses. Preliminary studies were carried out in mice immunized with VLPs formulated in either a surfactant-based emulsion or a block copolymer adjuvant. These adjuvants had a pronounced effect on antiparvovirus responses measured by ELISA and by RT-PCR neutralization (table 4) . A trend was observed between high capsid/high VP1 end-point titers by ELISA and in vitro neutralization, although no linear correlation was seen. Murine sera a Alum/VLP 62,500 12,500 500 Emulsion/VLP 312,500 62,500 1000 Copolymer/VLP 100,000 12,500 2500
NOTE. Human volunteers received 3 intramuscular vaccinations of 100 mg of VLPs in alum adjuvant. Anticapsid and anti-VP1 end-point titers were determined by ELISA as described in Materials and Methods.
a Pooled ( ); BALB/c mice received intramuscular vaccinations of VLPs n ϭ 5 formulated with experimental adjuvant as listed. To investigate further the relationship between adjuvant and anti-VLP response, a dose-escalating immunization study of VLP formulated with three different adjuvants (alum, block copolymer, or surfactant-based emulsion) was performed in rhesus monkeys (table 5) . Sera from rhesus monkeys immunized with VLP in emulsion or copolymer adjuvant demonstrated markedly enhanced antiparvovirus responses, with detectable in vitro neutralizing capacity after a single vaccination. Similar to results in human studies, antiparvovirus responses elicited by a single vaccination with alum-formulated VLPs were absent or just above background values. After two booster immunizations, sera from all 12 rhesus monkeys neutralized parvovirus in vitro, with ∼2-to 5-fold enhancement in copolymer and emulsion adjuvant recipients compared with alum recipients. End-point anticapsid ELISA titers after two booster immunizations ranged from 2500 (VLP in alum adjuvant) to 13,000,000 (VLP in emulsion adjuvant).
CFU-E analysis of selected rhesus sera after tertiary immunization was performed to confirm our RT-PCR neutralization results (figure 5). Sera with strong neutralizing activity by RT-PCR also protected erythroid progenitor cells in CFU-E. Rhesus sera with the lowest neutralizing scores by RT-PCR (alum adjuvant recipients) were found to be marginally protective or not protective by CFU-E, which may indicate the relative insensitivity of the colony-forming assay in detection of parvovirus-neutralizing activity.
Conclusions. The resolution of active infection and prevention of natural parvovirus B19 infection is dependent upon the production of antibodies directed to either one or both of the two capsid proteins VP1 and VP2. Passive administration of immune globulins containing anti-B19 reactivity to patients with active infection has been shown to abrogate viral replication and disease [7] [8] [9] [10] [11] . Developing an assay that quantifies this functional antiviral activity could have potential clinical value: to characterize surrogates for protection against infection, to identify individuals who may be at risk of infection (particularly those undergoing chemotherapy or with immune deficiencies), to assist in standardizing immune globulins for functional anti-B19 responses, and to guide vaccine design by setting standards of immune protection that should be achieved by active vaccination. The results described here begin to address many of these issues.
The RT-PCR assay developed was found to be a sensitive and quantitative method for B19 neutralization. Furthermore, larger numbers of samples could be evaluated simultaneously using this assay, compared with the conventional method using donor bone marrow cells. It is certainly feasible that other cell lines, besides UT-7, that are permissive for B19 infection [22, 23] might be useful in standardizing neutralization responses. Additional studies are warranted to establish reference standards for both viral replication and antibody activity, possibly with a neutralizing monoclonal antibody. The RT-PCR assay appears to be considerably more sensitive than the CFU-E assay in detecting functional neutralizing activity, since serum Downloaded from https://academic.oup.com/jid/article-abstract/179/3/619/807462 by guest on 18 December 2018 Figure 5 . CFU-E analysis of immune serum generated in rhesus monkeys. Erythroid progenitor cells obtained from primary bone marrow were incubated with B19 parvovirus and dilution of rhesus immune serum. Surviving erythroid cells were cultured in semisolid medium, and colonies from duplicate plates were counted. Colonies reported are sum of duplicate plates. VLP, virus-like particle; neut, neutralizing titer.
samples that failed to demonstrate any neutralizing responses in the latter had low neutralizing activity in this assay. Whether such titers are sufficient for in vivo protection will still need to be discerned, although titers achieved were well within the range of activity measured in randomly selected lots of immune globulin.
In vitro neutralizing titers, as expected, were identified only in subjects with measurable anticapsid antibodies. While particular individual sera with high binding titers to capsid components contained strong neutralizing activity, neither anti-VP1 specific titers nor anticapsid responses correlated directly with neutralizing titers. This suggests that varying responses are elicited in infected subjects to epitopes defining neutralizing domains. While previous studies with VLP vaccines have suggested that increasing the content of VP1 was important in enhancing neutralizing responses [15, 21] , functional anti-B19 activity after natural infection may provoke responses to both capsid proteins [24] [25] [26] [27] [28] . Also, it is unclear if the neutralizing responses in polyclonal sera are directed primarily to epitopes that are conformationally dependent or linear, since neutralizing monoclonal antibodies recognizing VP1 and VP2 have been identified that bind to both native and denatured VLP structures [29] . It will be of interest to define these neutralizing epitopes with regard to the required structure for optimal vaccine development.
The survey of neutralizing responses in sera from subjects suspected and observed to develop B19-associated disorders established a range for neutralizing responses required for recovery from acute infections. The maximum titer observed in these subjects was 1:5000, and most subjects had titers of р1:
1000. The titers observed in the immune globulin serum derived from large plasma pools of 11000 individuals were in a similar range, quite consistent with the titers of individual donors. These results establish the boundaries of titers that would be expected to yield effective responses after vaccination, given the effectiveness of random immune globulin pools in abrogating B19 replication. These titer ranges may also be of value in identifying individuals at high risk of developing B19 infections, particularly subjects with immune deficiency, those undergoing chemotherapy, or pregnant women. It was quite interesting, for example, that individuals with neutralizing titers of р1:200 developed documented B19 infections (table 2), although 1 subject with a baseline neutralizing value of 1:1000 also developed a rash-like illness. The limitation of these data is that primary serum samples were obtained after clinical illness was observed in most cases, and initial sampling may not represent accurate preexposure neutralizing levels.
The studies we report also demonstrated that two adjuvants other than alum markedly improved the induction of functional neutralizing responses to VLPs composed of the two B19 capsid proteins. While significant increases in neutralization were observed with both the blocked copolymer and the emulsion (MF59), in mice, the magnitude of the enhancement was even more pronounced in rhesus monkeys.
Several valuable observations emerged from this experiment. Anticapsid and neutralizing titers were low in the vaccine formulated in alum, comparable to what was observed in a clinical trial of seronegative volunteers immunized with a similar formulation. In fact, neutralizing activity in the clinical study was seen in a single volunteer and only after three immunizations; three doses of vaccine with alum adjuvant were required in rhesus monkeys to achieve consistent neutralizing responses. In contrast, neutralizing responses were observed in the majority of animals immunized with VLPs formulated in either of the experimental adjuvants after a single inoculation and were as high as any titer observed in naturally infected subjects after a booster vaccination. Furthermore, after a tertiary immunization, neutralizing titers in many of samples from the vaccinated monkeys exceeded any serum sample examined to date from humans previously infected with parvovirus B19. This would suggest that the formulation of either adjuvant with the B19 VLPs might induce effective functional responses in humans.
Of interest is the finding that despite the quantitative differences in the anticapsid responses induced by the two experimental adjuvants, neutralizing titers were quite similar with the two vaccine doses tested. It is possible that at doses !3 mg, differences in functional responses might be observed. In addition, the results suggest that MF59 might enhance responses to both neutralizing and nonneutralizing domains more effectively than the copolymer. Whether similar effects will be observed in human volunteers remains to be determined in future trials.
